Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Bexotegrast, Placebo matching PLN-74809
PLIANT THERAPEUTICS, INC.
Idiopathic pulmonary fibrosis (IPF)
1 trial -
BioFoam Surgical Matrix
United Therapeutics Europe Ltd
Intraoperative Bleeding
1 trial -
Biological Therapies Sodium Ascorbate Solution 30 g in 100 mL Injection, SODIUM CHLORIDE
Pari Pharma GmbH
Patient with sepsis complicated by ARDS
1 trial -
Biosteron, 10 mg, tabletki, Senaxa PR, 2 mg, tabletki o przedłużonym uwalnianiu
Lacuna Pharma Pty Ltd
Menopause, sleep disorders in the postmenopausal period
1 trial -
Bipap procedure
United Therapeutics Europe Ltd
Chronic Obstructive Pulmonary Disease
1 trial -
Bocouture, Placebo excipients (sucrose and human serum albumin) are reconstituted with sterile saline. Placebo vials will have identical appearance as the active product vials.
Merz Therapeutics GmbH
Moderate to Severe Platysma Prominence
1 trial -
Botulinum Toxin type A (intradermal / submucosal injection at pain area)
The First People's Hospital of Lianyungang
Trigeminal Neuralgia
1 trial -
Breathlessness Support Service
United Therapeutics Europe Ltd
Breathless Patients With Any Established Underlying Medical Diagnosis
1 trial -
Brief Strategic Family Therapy (BSFT)
BRIGHT MINDS BIOSCIENCES INC.
Substance Abuse
1 trial -
Budesonida Aldo-Unión 0,5 mg/ml suspensión para inhalación por nebulizador, CUROSURF® 120mg/vial + 240mg/vial Endotracheopulmonary Instillation Suspension
The George Institute
Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of gestational age.
1 trial -
Bupivacaine
United Therapeutics Europe Ltd
Postoperative Pain
1 trial -
Bupivacaine Liposome Injection
United Therapeutics Europe Ltd
Osteoarthritis
1 trial -
Busulfan (BU)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma
1 trial -
CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.
AstraZeneca AB
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
1 trial -
CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig
AstraZeneca AB
Unresectable Pleural Mesothelioma
1 trial -
CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB
BICYCLE THERAPEUTICS
Locally advanced or metastatic urothelial cancer
1 trial -
CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride
Sarepta Therapeutics
Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Psychosis
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Treatment Resistant Psychosis
1 trial -
CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME
Pari Pharma GmbH
antibiotic therapy in Sepsis
1 trial -
CELLULOSE, MICROCRYSTALLINE, OSELTAMIVIR , DEXAMETHASONE
The George Institute
Severe Influenza
1 trial -
CEP-33457
Teva Pharma GmbH
Systemic Lupus Erythematosus
2 trials -
CHAMPIX 0.5 mg film-coated tablets, Placebo CHAMPIX ® 0.5mg Comprimé pelliculé
Pari Pharma GmbH
Smokers smoking at least 10 cigarettes/day in the past year
1 trial -
CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab
The George Institute
patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources